SCHEMBL12797233

SCHEMBL12797233

Cc1cc(-c2cn3ccccc3n2)ccc1OCc1ccccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.59
RAB9A P51151 16/20 0.54
NPC1 O15118 15/20 0.54
SMN1; SMN2 Q16637 10/20 0.54
ALDH1A1 P00352 9/20 0.54
KDM4E B2RXH2 7/20 0.54
PKM P14618 5/20 0.54
MAPK1 P28482 2/20 0.54
TP53 P04637 1/20 0.54
HPGD P15428 1/20 0.54
TSHR P16473 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MAPT P10636 6/20 0.50
LMNA P02545 2/20 0.48
HTT P42858 1/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
GFER P55789 2/20 0.46
EPHX2 P34913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12797523 0.91 HRH3 (0.56) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12797519 0.91 HRH3 (0.56) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12797543 0.89 HRH3 (0.59) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12797517 0.89 HRH3 (0.55) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12797405 0.89 HRH3 (0.55) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12848765 0.88 RAB9A (0.68) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12797243 0.85 HRH3 (0.59) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12797212 0.84 HRH3 (0.63) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12797246 0.83 HRH3 (0.53) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12797236 0.83 HRH3 (0.57) HRH3RAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895599-B2 Lipoprotein lipase-activating compositions comprising benzene derivates OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2014-11-25 US disclosed
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2013-11-07 US disclosed
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES LPL, LIPC, LIPE HRH3 2016/4885RAB9A 3933/4885NPC1 366/4885
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES LPL, LIPC, LIPE HRH3 1936/4885RAB9A 3849/4885NPC1 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.